Bray GA, Kim KK, Wilding JPH
GIPR is expressed at low levels in some immune cells, predominantly in subsets of T cells and macrophages [139]
Rates of patients switching from AOM tirzepatide declined in the months following July 2025 and returned to near baseline levels by October, and growth in AOM tirzepatide prescribing rebounded after the initial decline
Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, et al
Tricare does not cover weight loss drugs at all for the following individuals: TRICARE For Life beneficiaries People with direct care coverage (military hospitals and clinics) Certain other groups (details are not specified) Tricare states that as of August 31, 2025, these groups will be required to pay 100% of the cost of weight loss medicineeven if a prior authorization had been previously approved
SEP-479 oral small-molecule agonist of the parathyroid hormone 1 receptor (PTH1R) aimed at treating hypoparathyroidism Recent Highlights: In May 2025, Septerna signed an exclusive global collaboration with Novo Nordisk worth up to $2.2B to co-develop oral small molecule GLP-1, GIP, and glucagon receptor agonists
.webp)
